磺胺葡聚糖(Sulforadex) - 药物靶点：HDACs_在研适应症：胶质母细胞瘤，神经发育障碍，自闭症谱系障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(-)-sulforaphane、(R)-sulforaphane、4-methylsulfinylbutyl isothiocyanate

+ [9]

靶点

HDACs

作用方式

抑制剂

作用机制

HDAC抑制剂(组蛋白去乙酰化酶家族抑制剂)

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症

胶质母细胞瘤神经发育障碍自闭症谱系障碍+ [1]

非在研适应症

急性髓性白血病自闭症新型冠状病毒感染+ [11]

原研机构

PharmAgra Labs, Inc.

在研机构

TheraCryf Plc

Stalicla SA初创企业

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C6H11NOS2

InChIKeySUVMJBTUFCVSAD-UHFFFAOYSA-N

CAS号4478-93-7

关联

73

项与磺胺葡聚糖相关的临床试验

NCT06594536

/ Not yet recruitingN/AIIT

Study of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity

ADHD is a neurodevelopmental disorder. It is the most common neurodevelopmental disorder in children and adolescents. Its prevalence is estimated at 5.9% in this population. The symptoms of ADHD combine attention deficit with behavioural disorders such as hyperactivity and impulsivity. Current treatment for ADHD is based on psychotherapeutic and psychoeducational measures aimed at improving behaviour and its impact on the family, social and school environment. Drug treatments may also be used, depending on the impact of the disorder and the effectiveness of alternative treatments. Psychostimulants such as amphetamine derivatives and methylphenidate are around 80% effective.
Sulforaphane is an active substance derived from broccoli that has already been tested in the treatment of other neurodevelopmental disorders. The main hypothesis is that sulforaphane is effective in treating the symptoms of Attention Deficit Disorder with or without Hyperactivity (ADHD) in children.

开始日期2024-12-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

ACTRN12624000812594

/ Not yet recruitingN/AIIT

Assessing the effects of a broccoli sprout extract on endothelial function in healthy non-pregnant and pregnant women, and pregnant women with a hypertensive disorder of pregnancy

开始日期2024-11-01

申办/合作机构

Monash Health

ACTRN12624000972527

/ Not yet recruitingN/AIIT

Targeting ferroptosis in diabetes and diabetic complications by hydrogen (per)sulfide in males 18 - 65 years old

开始日期2024-08-15

申办/合作机构-

100 项与磺胺葡聚糖相关的临床结果

登录后查看更多信息

100 项与磺胺葡聚糖相关的转化医学

登录后查看更多信息

100 项与磺胺葡聚糖相关的专利（医药）

登录后查看更多信息

4,273

项与磺胺葡聚糖相关的文献（医药）

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1

Article

作者: Zhang, Chang ; Cao, Deliang ; Hu, Wei ; Xia, Jiliang ; Li, Junjun ; Zhao, Hongyan ; He, Fen ; Sun, Jingqi ; Luo, Cong ; Zeng, Xi ; Sun, Weichu ; Lu, Zhongwei

PURPOSE:

Osteolysis is a common complication in patients with multiple myeloma (MM). Our previous studies have demonstrated that MM cells can promote osteoclast differentiation of macrophages. In this study, we explored the effect of sulforaphane (SFN), a natural NRF2 activator found in broccoli, on MM cell-induced osteoclast differentiation.

METHODS:

Conditional medium (CM) derived from MM cells was used to induce osteoclast differentiation, and TRAP staining was performed to examine osteoclast. Gene expression was detected by western blotting or real-time PCR. Cell counting and EdU staining were performed to test macrophage proliferation.

RESULTS:

We showed that the CM of MM cells downregulated the expression of ferroportin1 (Fpn1), the only known iron exporter in vertebrate cells, thereby increasing cellular iron levels in murine macrophage cells RAW264.7. Deferoxamine (DFO), an iron chelator, effectively blocked MM cell CM-induced osteoclast differentiation and macrophage proliferation, suggesting that iron overload played a key role in these cellular events. Subsequent mechanistic investigations revealed that MM cell CM induced osteoclast differentiation and macrophage proliferation by activating the JNK/AP-1/NFATC1 pathway and PI3K/AKT pathway. SFN was found to increase Fpn1 expression, leading to decreased cellular iron levels in RAW264.7 cells activated by MM cell CM. Importantly, the osteoclast differentiation and macrophage proliferation induced by MM cell CM were significantly inhibited by SFN.

CONCLUSION:

Altogether, our findings indicated that SFN inhibits MM cell-induced osteoclast differentiation and macrophage proliferation by elevating FPN1 levels. SFN could be a promising therapeutic strategy for MM-associated osteolysis.

2025-12-01·MOLECULAR BIOLOGY REPORTS

Protective role of sulforaphane in lipid metabolism-related diseases

Review

作者: Pronyuk, Khrystyna ; Zhao, Lingfeng ; Musabaev, Erkin ; Li, Jiahuan ; Fisher, David ; Zhao, Lei ; Dang, Yiping ; Hien, Nguyen Thi Thu

Sulforaphane (SFN) is a phytochemical bioactive substance commonly found in cruciferous plants, such as broccoli and mustard. It has been reported to possess antibacterial, anti-inflammatory, anti-oxidant, anti-cancer and autophagy regulating properties. Recent studies have revealed that SFN regulates fat metabolism both in vivo and in vitro through various mechanisms, including alleviating endoplasmic reticulum stress, inhibiting inflammatory response and improving mitochondrial dysfunction, involving Nrf2/ARE, NF-κB, NLRP3 inflammasome, HDAC8-PGC1α axis and other signaling pathways. By curbing complications associated with abnormal fat metabolic diseases, SFN exhibits therapeutic effects on conditions like obesity, fatty liver disease, atherosclerosis, type 2 diabetes, etc., with minimal side effects. Therefore, it holds promise as a potential alternative treatment for lipid metabolism-related diseases. Although its extraction method has been matured, the thermal instability and preservation difficulties of SFN limit its clinical promotion. More effective and low-cost methods to improve the stability and production of SFN remain to be further studied. This paper reviews the physiological and biological activities of SFN, and summarizes the protective effects and molecular mechanisms of SFN in diseases related to abnormal lipid metabolism. Additionally, it proposes potential challenges, possible solutions and future research directions in the clinical application of SFN.

2025-07-01·FOOD CHEMISTRY

The stability of isothiocyanates in broccoli extract: Oxidation from erucin to sulforaphane was discovered

Article

作者: Verheust, Yannick ; Sampers, Imca ; Song, Fanfen ; Raes, Katleen

The health-beneficial effects of Brassica vegetables are attributed to glucosinolates-derived isothiocyanates (ITCs) whose yield is always underestimated due to their reactivity and volatility. In this work, the distribution and stability of four ITCs, including allyl ITC (AITC), phenethyl ITC (PEITC), erucin (ERN), and sulforaphane (SFN), incorporated in water and broccoli extract were described. All ITCs were mainly distributed in the aqueous phase (> 99 %). AITC and PEITC exhibited similar stability in water and broccoli extract. However, an oxidation of ERN to SFN was observed in the broccoli extract, so a rapid decrease in ERN was observed while SFN experienced an increase before the decline. Except for ERN, all three ITCs become more labile when the pH increases from 3.4 to 8.4. Both oxygen and acid conditions promote the oxidation of ERN. Those results contribute to a better understanding of the stability and detection of ITCs in broccoli extract.

17

项与磺胺葡聚糖相关的新闻（医药）

2025-03-30

·生物谷

Nature子刊｜西兰花芽中的萝卜硫素或有助于降血糖，但效果因肠道微生物群而异

众所周知，糖尿病已成为全球范围内的重大健康问题。尤其是糖尿病前期人群，虽然血糖水平尚未达到糖尿病的诊断标准，但若不加以干预，患上2型糖尿病的风险极高。如何在糖尿病前期采取有效干预，帮助人们远离疾病困扰，一直是科学家关注的重点。近日，瑞典哥德堡大学的研究人员发现，西兰花芽中的一种化合物萝卜硫素可能有助于降低糖尿病前期患者的血糖水平，且该化合物对具有特定代谢类型和特定肠道细菌的人更有效。该研究题为“Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial”，发表在Nature microbiology杂志。图1：标题西兰花中的神秘成分西兰花中富含一种名为萝卜硫素（sulforaphane）的活性物质。早期研究发现，这种植物化合物不仅具有抗氧化、抗炎等多种生物学功能，还有助于抑制肝脏中糖异生的过程，从而降低血糖水平。此次，研究团队将目光聚焦于西兰花芽提取物（BSE），以进一步验证其对糖尿病前期人群的潜在作用。研究方法研究人员开展了一项随机、双盲、安慰剂对照试验。研究团队共招募了糖尿病前期且未接受药物治疗的个体，并将其随机分配至BSE组或安慰剂组。受试者每日服用相应试剂，持续干预12周。图2：以 CONSORT 图表示的研究概况为了确保研究的科学性，研究人员对受试者的饮食、运动及生活习惯进行了监测，最大程度上排除了其他因素对血糖水平的干扰。实验结束后，研究人员对两组受试者的空腹血糖水平、胰岛素敏感性等指标进行了详细分析。研究结果：BSE显著降低血糖水平实验结果表明，与对照组相比，BSE组受试者的空腹血糖水平显著降低。接下来，研究人员通过事后探索性分析研究了特定的临床和病理生理特征是否与对 BSE 的代谢反应有关。最后，51 名研究参与者（29 名 BSE，22 名对照组）具有轻度与年龄相关的糖尿病 (MARD) 的典型特征，BMI、胰岛素抵抗、脂肪肝指数和胰岛素分泌相对较低。更有趣的是，进一步分析显示，BSE的疗效与受试者肠道微生物群的组成密切相关。图3：参与者分布和肠道微生物群组成研究人员发现，某些有益菌群（如Levilactobacillus和Lactiplantibacillus ）的丰富度较高者，其血糖水平下降的幅度更明显。也就是说，肠道菌群的差异可能直接影响BSE的降血糖效果。这一发现进一步揭示了肠道微生物在代谢健康中的关键作用，为糖尿病的个性化治疗带来了新的思路。尽管具有 MARD 样特征的参与者对 BSE 的平均血糖反应更大，但所有具有 MARD 样特征的个体的反应并不一样。为了进一步了解除了病理生理集群之外，哪些因素会影响血糖反应，作者在事后分析中对比了对 BSE 表现出明显反应的参与者与其余参与者。在 13 位明显反应者中，11 位属于具有 MARD 样特征的集群，进一步证实了 MARD 特征对治疗反应很重要。此外，作者观察到明显反应者的基线肠道菌群组成与其余者有显著差异，治疗后没有进一步变化。图4：对 BSE 有不同反应的参与者的肠道菌群概况研究的局限性与未来展望尽管BSE在本次试验中展现出积极的血糖调节效果，但研究人员也指出，仍需进一步探索其在更大样本量及长期干预中的安全性和有效性。此外，肠道菌群的个体差异可能会导致不同人群对BSE反应存在显著差异，这为个性化治疗提供了新的思路。未来，科学家们计划开展更大规模的临床试验，以确认BSE的长期疗效，并深入探讨其作用机制。同时，针对肠道菌群的研究也有望为糖尿病治疗开辟更加精准的干预策略。结论：西兰花，或成糖尿病干预“新星”本次研究不仅证实了西兰花芽提取物在降血糖方面的积极作用，还进一步揭示了肠道菌群在糖尿病干预中的关键影响。作为一种天然来源的植物提取物，BSE的安全性和耐受性较高，或许能成为未来糖尿病前期人群的重要干预手段。不过，研究人员也提醒，尽管BSE显示出较好的疗效，但不应将其视为糖尿病治疗的“特效药”，更不能替代健康的生活方式。通过均衡饮食、适量运动及良好生活习惯，才能真正将糖尿病的风险降到最低。参考来源：Dwibedi, C., Axelsson, A.S., Abrahamsson, B. et al. Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial. Nat Microbiol 10, 681–693 (2025). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41564-025-01932-w撰文｜Catherine编辑｜小饼干来源｜梅斯学术本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！

临床研究微生物疗法

2025-02-17

·生物世界

Nature子刊：临床研究显示，西兰花或可预防糖尿病，具体效果与肠道菌群有关

撰文丨王聪编辑丨王多鱼排版丨水成文糖尿病前期（Prediabetes）是指血糖水平高于正常，但尚未达到糖尿病诊断标准的状态。糖尿病前期患者有较高的风险发展为 2 型糖尿病，因此寻找有效的干预措施至关重要。西兰花芽提取物（broccoli sprout extract，BSE）中含有一种名为萝卜硫素（sulforaphane）的化合物，已知其在 2 型糖尿病患者中可以减少肝脏葡萄糖生成（糖异生），并且耐受性良好。 2025 年 2 月 10 日，哥德堡大学的研究人员在 Nature 子刊 Nature Microbiology 上发表了题为：Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial（西兰花芽提取物和基线肠道微生物群对糖尿病前期空腹血糖的影响：一项随机、安慰剂对照试验）的研究论文。这项研究表明，西兰花芽提取物（BSE）对糖尿病前期患者的空腹血糖有一定的降低作用，但其效果因个体的病理生理特征和肠道微生物群组成而异。这项研究旨在探讨西兰花芽提取物（BSE）对糖尿病前期患者的空腹血糖的影响，并分析肠道微生物群在这一过程中的作用。研究团队进行了一项随机、双盲、安慰剂对照的临床试验，研究对象为未接受过药物治疗的糖尿病前期患者。研究团队将 89 名患者随机分为两组，一组接受 BSE 治疗（n=35），另一组接受安慰剂（n=39），每天一次，持续 12 周。主要研究终点是空腹血糖从基线到第 12 周的变化。结果显示，BSE 组的空腹血糖平均降低了 0.2 mmol/L，但未达到预设的主要终点（0.3 mmol/L的降低）。研究团队通过数据驱动的聚类分析，将患者分为不同的病理生理亚组。结果显示，具有轻度肥胖、低胰岛素抵抗和胰岛素分泌减少的患者（称为“应答者”）对 BSE 的反应更为显著，空腹血糖平均降低了 0.4 mmol/L。此外，进一步的肠道微生物群分析显示，“应答者”的基线肠道微生物群组成与“非应答者”不同，“应答者”具有更高丰度的拟杆菌编码的将无活性前体转化为生物活性萝卜硫素所必需的转录调控因子（操纵子BT2160），且其丰度与血清中萝卜硫素的浓度相关。总的来说，该研究表明，西兰花芽提取物（BSE）对糖尿病前期患者的空腹血糖有一定的降低作用，但其效果因个体的病理生理特征和肠道微生物群组成而异。特别是具有轻度肥胖和低胰岛素抵抗特征的患者对 BSE 的反应更为显著。此外，肠道微生物群中的操纵子 BT2160 可能在这一过程中发挥了关键作用。这项研究为糖尿病前期的个性化治疗提供了新的思路，强调了在干预措施中考虑个体病理生理特征和肠道微生物群的重要性。未来的研究需要进一步验证这些发现，并探索 BSE 在糖尿病预防中的长期效果。论文链接： https://www-nature-com.libproxy1.nus.edu.sg/articles/s41564-025-01932-w 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

临床结果微生物疗法临床2期

2024-03-04

·BioSpace

Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

Latest Patent to Complement Issued Claims on Viral Inhibition, Adaptive Immune Stimulation, and Brain Protection/Regeneration ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19. NK cells are the first line of defense against viruses and cancers1. The Company was previously awarded by the United States Patent and Trademark Office the following QuadraMune® related patents: Patent #11,229,674, covering inhibition of the immune suppressing enzyme indolamine 2,3 dioxygenase2. It is published that this enzyme plays a fundamental role in immune suppression by cancer3, as well as numerous viruses including SARS-CoV-2, the causative agent of COVID-194. Patent #11,266,707, “Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19”5. Patent #11,504,410, covering use of QuadraMune® and its derivatives for protecting and restoring brain function after neurological damage, including Long COVID6. Patent #11759495, covering upregulation of T regulatory cells for suppression of suicidal ideation7. “In addition to this important validation from the USPTO, the fact that the ingredients in QuadraMune® have been reported by institutions such as Johns Hopkins University to suppress SARS-CoV-2 is strongly encouraging,” said Famela Ramos, Vice President of Business Development for the Company. “Our Company is driven by a desire to address unmet medical needs, whether it is through developing state of the art stem cell and gene therapies, or science-backed nutraceuticals,” said Timothy Dixon, President, and CEO of the Company. “The importance of NK cells in protecting the body against cancer and viruses is well known, the fact that this can be performed using a low-cost nutraceutical approach has implications in both oncology and virology.” About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is . 1 Cerwenka and Lanier. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001 Oct;1(1):41-9. 2 3 Ricuitti et al. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. Pharmacol Ther. 2019 Apr:196:105-116. 4 Guo et al. Indoleamine 2,3-dioxygenase (IDO)-1 and IDO-2 activity and severe course of COVID-19. J Pathol. 2022 Mar;256(3):256-261. 5 6 7 8 Johns Hopkins University Publishes Efficacy of QuadraMune™ Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies | BioSpace

免疫疗法

100 项与磺胺葡聚糖相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12422

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	英国	TheraCryf Plc	2020-11-23
成人呼吸窘迫综合征	临床3期	英国	TheraCryf Plc	2020-11-23
SARS-CoV-2 急性呼吸道疾病	临床3期	英国	TheraCryf Plc	2020-09-19
ER阳性/HER2阴性乳腺癌	临床2期	比利时	TheraCryf Plc	2016-10-01
ER阳性/HER2阴性乳腺癌	临床2期	法国	TheraCryf Plc	2016-10-01
ER阳性/HER2阴性乳腺癌	临床2期	西班牙	TheraCryf Plc	2016-10-01
ER阳性/HER2阴性乳腺癌	临床2期	英国	TheraCryf Plc	2016-10-01
转移性乳腺癌	临床2期	比利时	TheraCryf Plc	2016-10-01
转移性乳腺癌	临床2期	法国	TheraCryf Plc	2016-10-01
转移性乳腺癌	临床2期	西班牙	TheraCryf Plc	2016-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2025	N/A	胰腺腺癌	-	Non-Thermal Plasma (NTP) + Tirapazamine (TPZ)	艱顧構齋膚壓鑰鬱窪醖(積鏇積願夢鏇鏇簾築構) = 觸憲選簾簾鹽壓願願構獵衊齋襯醖醖憲願憲蓋 (築蓋齋遞鑰繭衊積壓淵 ) 更多	积极	2025-04-28
NCT03232138 (CTgov)	临床2期	肺癌	43	Sulforaphane (Sulforaphane (Study Drug))	繭遞襯製選廠齋衊淵製(簾窪鏇醖繭壓壓範壓蓋) = 願築繭糧廠選簾廠窪鹽繭膚選獵衊鹹蓋鏇觸鹽 (壓艱網網窪繭觸壓蓋獵, 0.38) 更多	-	2025-03-25
				Placebo (Placebo)	繭遞襯製選廠齋衊淵製(簾窪鏇醖繭壓壓範壓蓋) = 觸遞襯壓夢憲糧憲衊鑰繭膚選獵衊鹹蓋鏇觸鹽 (壓艱網網窪繭觸壓蓋獵, 0.41) 更多
NCT05153174 (CTgov)	临床1期	慢性肾病	18	Sulforaphane (2 Tablets of Sulforaphane)	襯壓範淵觸壓繭窪鹹衊(夢淵製鑰製艱積範醖選) = 顧衊範窪遞遞廠膚遞願淵膚顧構艱夢製繭鹹構 (顧簾繭簾糧膚構網選襯, 376.5) 更多	-	2024-08-12
				Sulforaphane (4 Tablets of Sulforaphane)	襯壓範淵觸壓繭窪鹹衊(夢淵製鑰製艱積範醖選) = 製膚齋願膚蓋鹽鏇襯餘淵膚顧構艱夢製繭鹹構 (顧簾繭簾糧膚構網選襯, 335.8) 更多
NCT02614742 (SAS Study, Pubmed)	临床2期	蛛网膜下腔出血	105	SFX-01 300 mg BD	製夢鏇選齋鬱蓋簾觸壓(膚鑰製觸網鏇膚鹹窪衊) = 9 SFX-01 (16.7%), 1 placebo (2.0%) 範鏇餘夢繭繭淵襯築膚 (簾遞蓋獵構衊製願壓餘 )	不佳	2024-07-19
ERS2022	N/A	新型冠状病毒感染	133	S-SFN 300mg	廠襯壓膚艱遞鏇繭衊廠(範製積鹽選鹽廠蓋鏇憲) = 範鏇淵齋範觸遞網糧廠蓋簾蓋淵製蓋觸獵鏇選 (獵衊膚衊網艱窪淵鹹淵 )	不佳	2022-09-04
				Placebo	廠襯壓膚艱遞鏇繭衊廠(範製積鹽選鹽廠蓋鏇憲) = 鹽壓繭築艱繭願獵齋簾蓋簾蓋淵製蓋觸獵鏇選 (獵衊膚衊網艱窪淵鹹淵 )
EASD2021	N/A	-	-	Alpha-cyclodextrin 2g/kg	顧窪淵窪積醖觸艱蓋範(窪顧鹹衊壓範積範衊構) = 願鹽範窪願鬱廠淵鏇鏇選觸壓獵簾艱齋簾製積 (選製鹹範製餘醖鑰網蓋, 4.05)	-	2021-09-28
NCT02561481 (Pubmed \| Mol Autism) 人工标引	临床1/2期	自闭症谱系障碍	57	sulforaphane	鹹蓋獵製簾網築壓壓憲(選鑰廠鹽餘遞膚範簾鏇) = 壓鬱鏇簾鹽構觸築選獵醖齋範醖範築遞膚糧憲 (鬱願艱繭壓構鹽艱製鏇, -0.46 ~ 0.88) 更多	不佳	2021-05-25
				Placebo	鹹蓋獵製簾網築壓壓憲(選鑰廠鹽餘遞膚範簾鏇) = 齋範糧窪廠網壓築製夢醖齋範醖範築遞膚糧憲 (鬱願艱繭壓構鹽艱製鏇, -0.52 ~ 0.72)
NCT02561481 (CTgov)	临床1/2期	自闭症谱系障碍	60	Sulforaphane (Sulforaphane)	顧鹽鹽鹹築鏇遞衊淵夢(鬱憲簾蓋醖廠積觸鹹鹹) = 選鏇衊襯鹹繭廠壓構鏇願蓋築積蓋壓壓網鬱構 (壓鹽窪夢醖積網遞鬱夢, 0.67) 更多	-	2020-11-25
				Placebo (Placebo)	顧鹽鹽鹹築鏇遞衊淵夢(鬱憲簾蓋醖廠積觸鹹鹹) = 襯廠鹽選醖餘憲糧膚遞願蓋築積蓋壓壓網鬱構 (壓鹽窪夢醖積網遞鬱夢, 0.57) 更多
NCT02909959 (CTgov)	临床2期	自闭症谱系障碍 \| 自闭症 \| 普遍的儿童发育障碍	48	Sulforaphane (Sulforaphane)	鑰衊憲選鹽淵夢鹹醖憲(艱鹹簾膚顧膚簾構積鏇) = 夢鹹壓鬱範襯顧製顧觸願齋繭襯遞遞選遞築醖 (鑰夢鏇積廠構窪艱蓋鏇, 7.4) 更多	-	2020-05-15
				Placebo (Placebo)	鑰衊憲選鹽淵夢鹹醖憲(艱鹹簾膚顧膚簾構積鏇) = 淵憲顧膚糧衊範鏇窪衊願齋繭襯遞遞選遞築醖 (鑰夢鏇積廠構窪艱蓋鏇, 4.6) 更多
NCT02970682 (STEM, ESMO2019) 人工标引	临床2期	HER2阳性转移性乳腺癌 ER Positive \| HER2 Negative	46	Aromatase Inhibitors+SFX-01	鬱鹽願淵憲憲鬱艱廠顧(壓製遞選獵艱築蓋憲築) = SFX-01 was well tolerated with grade 1/2 nausea (54.3%) and dyspepsia (32.6%) the most frequent adverse events (AEs). 餘淵襯夢窪鏇鬱鹹膚夢 (夢鹹網糧壓遞顧鑰夢憲 )	积极	2019-09-29
				Tamoxifen+SFX-01